Tumor cells can evade immune surveillance by secreting immuno-suppressive factors such as transforming growth factor-beta (TGF-β) and also, Interlukin-10 (IL-10). In this paper the optimal control of mathematical model for aggressive tumor growth via a new and proper approach known as AVK method has been considered. Moreover, we have implemented a special treatment so-called small interfering RNA (siRNA) to reduce presence and effect of TGF-β in tumor cells and also we have added Interlukin-2 (IL-2) into our treatment model to minimize the population of tumor cells. Further research and experimentation with these combination therapies may provide an effective solution in addressing the immuno-suppressive effects of TGF-β. Finally, we analyze the optimal control and system optimality of these equations using numerical techniques.
Introduction
The concept of immunotherapy is based on the body's natural defense system, which protects us against a variety of diseases. Although we are less aware of it, the immune system also works to aid our recovery from many illnesses. Immunotherapy falls into three main categories: Immune cell-stimulating cytokines, monoclonal antibodies, and vaccines. Cytokines are a number of small proteins that carry signals locally between cells, and thus have an effect on other cells [1] . Interleukin-2 (IL-2) is the main cytokine responsible for lymphocyte activation, growth and differentiation. IL-2 unlike classical chemotherapy does not kill tumor cells directly. Instead, IL-2 activates and stimulates the growth of immune cells, Natural Killer Cells (NK Cells) and most importantly T-Cells which are capable of destroying cancer cells directly [1] . Transforming growth factor-beta (TGF-) is also one of the family cytokines, which are present in both healthy and tumor cells [2, 3] . Although TGF-β promotes healthy cell growth and function, the production of TGF- by tumor cells greatly challenges the immune system through the promotion of angiogenesis, enhancing tumor growth and metastasis [2] . In recent years several papers have begun to investigate the various aspects of the immune system response to cancer from a mathematical perspective. One of the first attempts to consider effects of immunotherapy was presented by Kirschner and Panetta. They study on the role of IL-2 adding with adoptive cellular immunotherapy (ACI) [4] . Sarkar and Banerjee, expressed the model which consist of three ordinary differential equations, tumor cells, hunting predator cells and resting predator cells [5] . Capputio et al. analyzed the interaction between NK cells, 8 
CD
 cells and effect of Interlukin-21 (IL-21) in immunotherapy of tumor growth. They investigated effect of IL-21 on tumor cells. Then a year later they suggested optimal treatment of tumor cells via IL-21 [6] . In 2009 a mathematical models was presented by Jushi et al. They develop a new mathematical model of immunotherapy and cancer vaccination, focusing on the role of antigen presentation and co-stimulatory signaling pathways in cancer immunology [7] . Finally lets us to mention a recent paper by Arciero et al. which is presented a novel treatment strategy known as small interfering RNA (siRNA) therapy [8] .Their model predicts conditions under which siRNA treatment can be successful in transformation of TGF-b producing tumors to either nonproducing or producing a small value of TGF-b tumors, that is to a non-immune evading state.
In this paper, we try to extend the model of aggressive tumors presented by Arciero et al. [8] and add IL-2 in their mathematical model to enhance ability of immune systems. We will implement optimal control theory for decreasing the population of tumors cell. Finally we de-
Immunotherapy of Tumors siRNA
Through small interfering RNA (siRNA) treatment the initial delivery of double-stranded RNA (dsRNA) are taken into tumor cells (see Figure 1) . Then the dsRNA is divided into 21 -23 nucleotide-long segments known as siRNAs by enzyme Dicer. In that sense, enzyme Dicer target TGF-β mRNA once bound to the RNA-induced silencing complex (RISC) [5] . Complementary mRNA strands which is coded for TGF-β within tumor cells are determined by siRNA, subsequently, the RISC binds to and cleaves the mRNA to prevent production of TGF-β protein. Ultimately, siRNA treatment works to target the specific mRNA due to inhibiting TGF-β expression. Nevertheless, some drawbacks exist in this therapeutic strategy that may limit the effectiveness of it, such as the accessibility of siRNA target sites on TGF-β mRNA [9] . Moreover, cytokine therapy (e.g. IL-2 therapy) can be administered in combination with siRNA treatment, to not only inhibit the production and immuno-suppressive effects of TGF-β but also, increase ability of immune systems [2] .
Aggressive Tumor Model
Aggressive tumor can produce TGF-β which is causing increased tumor growth from angiogenesis and the increased ability of the tumor to escape detection by the immune system due to immuno-suppressive properties. In [4] the mathematical model of passive tumors includeing effector cells, tumor cells and IL-2 are presented. In this paper we present a mathematical model for aggressive tumor where E(t) is effector cells as a immune system of body, T(t) is tumor cells, I(t) is IL-2, and S(t) is related to production of TGF-β as a immuno-suppressive factor [8] .
In Equation (1), effector cells are assumed to be informed of the tumor site in case the tumor cells are existed. The parameter c in the first term of Equation (1), measures the ability of the immune system to recognize tumor cells which is known as antigenicty of the tumor. Inhibitory parameter γ is a factor to show production of TGF-β which is lead to decrease antigen expression [2] . The second term represents the mortality rate of effector cells. The third term, Michaelis-Menten forms of components, presents effector cell proliferation due to presence of the cytokine IL-2 that can decrease when the cytokine TGF-β is produced. Where p 1 is the maximum rate of effector cell, g 1 and q 2 are half-saturation constants, and q 1 is the maximum rate of anti-proliferative effect of TGF-β.
Equation (2) is related to the growth of the tumor cells. The first term represents logistic growth of tumor cells where r is intrinsic growth rate and K is carrying capacity of tumor in the absence of effector cells and TGF-β (or every simulated factor). The second term describes the reduction of the tumor population depends on immune clearance. The interaction between immune response and tumor cells is measured by parameter a [4] . The third term in Equation (2) accounts for the increased growth of tumor cells because of TGF-β production. In fact, TGF-β is a factor helps tumor cells to exceed their size. This term is a form of Michaelis-Menten which indicates a limited response of tumor cells to a growth-stimulatory cytokine like TGF-β. Also, p 2 is the maximum rate of increased proliferation and g 3 is the half-saturation constant.
In Equation (3) the kinetics of IL-2 is explained. The first term shows IL-2 production with a maximum rate of p 3 in the presence of effector cells stimulated and with a half-saturation constant g 4 without considering TGF-β as a limited cause. In addition, parameter α measured the inhibition of IL-2 production in presence of TGF-β in an uncompetitive manner. In last term, the decay rate of IL-2 is represented by μ 2 .
Equation (4) describes the rate of change in producing suppressor cytokine, TGF-β with p 4 as the maximum rate of TGF-β production and  c as the critical tumor cell population in which the switch occurs. Furthermore, μ 3 represented the decay rate of TGF-β [8] . For more details Copyright © 2012 SciRes.
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about parameters which are used in these equations we can say that where it is possible, these parameters are taken from the medical literature and articles, and when there are unavailable experimental data for some pa-rameters, we consider our goal to quantify the parameters influence on the model behavior. Table 1 lists the baseline values of the model parameters used in the numerical simulations. Briefly, values for the parameters are used without considering last equation. It means that we assume . The equations are nondimensionalized as follows [8] : (5) Then, without considering over-bar notation for convenience, the system of tumor growth in the absence of treatment is represented as below [8] :
With initial conditions
In this section, we describe the case in which tumors become aggressive and interfere the body's immune response when TGF-β is produced, tumor mass has enough potential to grow near its carrying capacity and this situation can occur for all tumors at some p 4 value, regardless of the level of antigenicity. The three figures illustrate the different results when increasing the rate of TGF-β production (p 4 ) for various values of antigenicity (c). In Figure 2 , the value of c and p 4 are very small (c = 1 × 10 -10 ). Therefore, tumor cannot be detected by the immune system. This result in rapid tumor growth quickly approaches its carrying capacity. immune system has ability to control the tumor population. Tumor's behavior has damped oscillations and shows downward trend. This manner sometimes is described as dormant. However, if p 4 increases, the immune system is no longer successful in defeating the tumor, and large tumor mass again characterizes the tumor behavior near carrying capacity.
Optimal Treatment of Tumors Using siRNA and IL-2
In this section we have provided one of the mathematical models of aggressive tumor growth that implements siRNA treatment to suppress TGF-β production. In this paper, we incorporate IL-2 by defining a controller to the model. While not yielding persistent dormancy, siRNA offers a treatment technique that counteracts the devastating effects of TGF-β, such as IL-2 inhibition and increased tumor growth. Variable of u(t) is percentage of applying drug during immunotherapy that we expected to achieve the existing status of patient . Therefore, we define a mathematical model Equations (14)-(18), including siRNA to suppress effects of TGF-β at tumor cells and also, IL-2 to enhance effects of immune system. Notice that the first three equations correspond to Equations (1), (2) and (3). Moreover, Equation (13) is modified version of Equation (4) that concentrates on cytokine TGF-β [8] .
In the first term of Equation (13), the production of TGF-β due to effects of siRNA is inhibited; indeed, siRNA is bound to target TGF-β mRNA. Variable A represents total strands of siRNA, free and bound strands, and parameter f shows the proportion of variable A which is bound. Thus, the bound siRNA strands are described by fA, and k i measures inhibition rate of siRNA as a suppressive factor.
Equation (14) represents the injection and degradation of the siRNA. D 1 describes a continuous infusion dose of siRNAs as a function of time. So, D 1 (t) = D 0 ≡ constant. In fact, D 0 is the injected dose. The second term, μ 4, represents the decay of the free siRNA strands based on their half life which is estimated of 0.66 days −1 [10] . Also, in many vitro studies siRNA treatment have determined with an initial dose of 2 × 10 9 pg/ml of siRNA [11] ; therefore, we take D 0 = 5 × 10 10 pg/ml as a comparable dose for an in vivo system. u(t) is a control function that explains percentage of using IL-2 and in this paper we recognize it as a continuous step function of time for each t relating to treatment period 
Then, without considering the over-bar notation for convenience, the system describing tumor evasion of immune surveillance in the presence of siRNA treatment may be written as follows:
We can attain v(t) by solving Equation (20) according to value of its parameters ( 0 and i  ) and then put it in Equation (19). Consequently,
Often controllable problems have large dimensions and analyzing them is difficult so we try to estimate a control problem with linear programming then explain it via numerical results. In this method we first estimate our problem with calculus of variations then convert it with a linear programming problem. If the optimal answer of linear programming problem is zero or near zero, we can conduct system from one condition to another. Moreover answer of linear programming problem can provide proper estimation and desirable control of system. Attending to this subject, we can apply discriminating method for nonlinear systems, therefore in this paper we estimate mathematical model of tumor growths via AVK method [12] to nonlinear programming problem afterwards we can solve the nonlinear programming problem by LINGO software. We can approach exact answer of differential equation systems and achieve accuracy estimation by increasing the number of division points in range [a, b].
Objective Function and Multi Objective Optimal Control
In this paper, we use control rule of u(t) for decreasing tumor size via mathematical model, tumor size is decreased, and the prescribed dose is determined for the patient simultaneously. Therefore we intend to minimize multi objective optimization (Equation (21)) attentive to and weights  1 = 0.8 and w 2 = 0.2, so in this case we consider significance of minimizing tumor cells more than dose of prescription IL-2. Purpose of introducing this objective function is to decrease tumor cell population and amount of TGF- by using external drug source whereas effector cells and IL-2 is sufficiently increased on round of treatment.
AVK Method
Definition 1: We focus on following nonlinear problems with uncertain parameter (NPUP)
X and U are compact subsets and must be chosen as the system reaches from initial state x(t 0 ) = x a to final state x(t f ) = x b . Definition 2: First, consider nonlinear system (22), we define following functional that is called the total error functional. Let
is a continuous functional.
Definition 3: The solution of uncertainty problem can track the desired curve x d (t), if we consider a multi objective functional as
Definition 4: If t has  known distributed function similar to g(t), we may define new functional: In AVK method, the following problem is defined in calculus of variations:
. . 0 , 1 ;
or all uncertain values,
is a distribution function. We assume the optimal solution of problem (26) is x*(t), u*(t), the state and the control functions, respectively. According to Theorems 1 and 2:
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Conclusion
The aim of this paper was to exhibit a new and proper approach, known as AVK method, which could solve the nonlinear equations without changing its structure. The fairly proper efficiency of this suggested method was shown by numerical results. As was described, siRNA treatment inhibits the production and immuno-suppressive effects of TGF-β by targeting the specific mRNA sequence which leads to its synthesis. Furthermore, adding IL-2 in to the model could result in controlling tumor by enhancing an immune response. The mathematical model of aggressive tumor was extended to include therapeutic strategy using siRNA and IL-2.
Suggestion
An extension along this line of work will be to examine the effect of other cytokines such as IL-10, IL-12 and interferon-, which are involved in the cellular dynamics of the immune system response to tumor invasion and how these cytokines affect the dynamics of the system. For future study, the addition of each cytokine above with other treatments such as chemotherapy and radiotherapy into our treatment model could result in actual tumor clearance.
